Altimmune earnings date
Altimmune (3G0) Q3 2026 Earnings Report
DE:3G0 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.14
- Consensus EPS
- -EUR 0.12
- Beat/Miss
- Missed by -EUR 0.02
- One Year Ago EPS
- -EUR 0.19
DE:3G0 Q3 2026 Revenue Results
- Actual Revenue
- EUR 0
- Expected Revenue
- EUR 0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- -100.00%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Altimmune's next earnings date is estimated for March 3, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly optimistic about pemvidutide's clinical differentiation and development progress. Management highlighted positive MASH and AUD data, expanding clinical execution, strong investigator engagement, a substantial AUD opportunity, and sufficient cash runway through the planned MASH readout. The principal negatives were higher operating expenses, a larger absolute quarterly net loss, low MASH diagnosis and treatment rates, ongoing tolerability evaluation, and the lack of a firm AUD Phase 3 start date or funding plan. Overall, the highlights significantly outweighed the lowlights.
Management expects the PERFORMA 52-week data readout in 2029, with enrollment taking an 18 to 24 month range; over 70 US sites are activated, roughly 1 third of the ultimate study sites will be in The US, and ex US sites are expected to activate over the coming months. For AUD, the end of phase 2 meeting with the FDA is scheduled for December, meeting minutes typically follow within 30 days, and EMA dialogue is anticipated in the first quarter; the expected PROCURE design includes 1.8 milligram and 4 mg doses with a simple 1 to 2 step titration, a primary efficacy read at 26 weeks, and continuation up to 1 year. RESTORE top line data are expected in the second half of 27, and $480 million in cash equivalents and investments is expected to provide operating runway through the PERFORMA Phase 3 MASH 52-week data readout expected in 2029.
- Pemvidutide Development Progress Across Three Liver IndicationsManagement said it significantly advanced pemvidutide programs across NASH, AUD, and ALD during 2026, strengthening its belief that the product can support a broad liver franchise with multiple indications in serious liver diseases.
- Positive MASH Data and Antifibrotic ActivityNew 48-week IMPACT data presented at The Liver Meeting showed concurrent improvement across multiple non-invasive measures of liver fat, inflammation, and fibrosis versus placebo. Management highlighted strong and consistent antifibrotic activity, including approximately 3 to almost 4 kilopascals of improvement at the 1.8 milligram dose.
- PERFORMA Phase 3 Trial Advancing as PlannedThe global PERFORMA Phase 3 MASH trial is screening and dosing patients, with clinical site activation continuing according to plan. More than 70 U.S. sites were activated, the majority of planned U.S. sites were recruiting, and ex-U.S. site activation is expected over the coming months. The 52-week data readout remains anticipated in 2029.
- Positive Investigator and Scientific Community EngagementManagement reported strong enthusiasm and engagement from PERFORMA investigators, clinical sites, key opinion leaders, and the broader NASH community. The company also reported a well-attended disease-state product theater at The Liver Meeting focused on the overlap among metabolic dysfunction, alcohol consumption, and serious liver disease.
- IMPACT Data Published in The LancetThe 48-week IMPACT Phase 2b efficacy and safety data were published in The Lancet during the week of the call.
- RECLAIM AUD Results Were Statistically SignificantThe RECLAIM Phase 2 trial showed statistically significant improvements in heavy drinking days and key secondary measures, including WHO risk drinking level achievement and zero heavy drinking days. Both cited measures were described as FDA registrational endpoints.
- Objective Alcohol-Consumption Measure Corroborated ResultsPEth, an objective serum-based measure of alcohol consumption, corroborated the self-reported reduction in alcohol intake among pemvidutide-treated patients. Pemvidutide also increased abstinence in patients with AUD.
- Potential Liver Benefits Observed in RECLAIMAlthough RECLAIM focused on drinking behaviors, an exploratory analysis showed that pemvidutide decreased the proportion of patients at elevated risk of developing advanced liver fibrosis as measured by FIB-4.
- AUD Regulatory Engagement ScheduledThe end-of-Phase 2 meeting with the FDA for AUD is scheduled for December, with meeting minutes typically expected within 30 days. Management also anticipates dialogue with the EMA in the first quarter.
- Planned AUD Phase 3 Design Includes Liver-Impaired PatientsThe planned AUD registrational program is expected to focus on moderate-to-severe AUD and include a subpopulation with advanced liver impairment, including ALD. The anticipated primary endpoint is WHO risk drinking level, with no heavy drinking days as a key secondary endpoint; planned doses are 1.8 milligrams and 4 milligrams with one- to two-step titration.
- RESTORE ALD Trial Fully EnrolledThe RESTORE trial enrolled 121 patients with ALD and a history of chronic and heavy drinking at baseline. The 48-week trial is designed to evaluate liver benefit, with additional assessments at 24 weeks, and topline data are expected in the second half of 2027.
- Differentiated Mechanism and Product ProfileManagement emphasized pemvidutide's balanced 1-to-1 glucagon-to-GLP-1 ratio and proprietary UPORT domain, which it said provide metabolic and liver-directed activity with a generally favorable tolerability profile. The company also highlighted a lack of significant drug interactions and simple dosing.
- Potential Combination-Therapy Positioning in MASHManagement said pemvidutide's dual mechanism, generally favorable tolerability, and lack of significant drug interactions could support a future role as a potential combination therapy for MASH patients who do not reach therapeutic goals or cannot tolerate current therapy.
- Large Addressable AUD Population and Early-Mover PositionManagement cited approximately 27 million Americans who meet the criteria for AUD, including approximately 12 million with moderate-to-severe AUD. It described pemvidutide's early-mover status in AUD as a competitive advantage and said only approximately 2.2% to 2.5% of AUD patients meeting the criteria currently receive pharmacotherapy.
- Substantial AUD and ALD Population OverlapManagement cited estimates that 55% to 94% of ALD patients also meet the criteria for AUD, supporting the company's focus on a patient continuum involving alcohol consumption and alcohol-related liver damage.
- Broad AUD Response Across Patient SubgroupsThe company said RECLAIM results were remarkably consistent across different measures and subpopulations, including gender and BMI. Based on the data, the planned Phase 3 AUD program is expected to explore patients with BMI below 25 or normal BMI.
- Expanded Safety Exposure and Potential Use of Existing DataManagement stated that more than 750 patients have already been exposed to pemvidutide and expects to discuss with regulators whether safety exposure from MASH and prior Phase 2 trials can be used to limit the additional safety database required for the AUD program.
- Board Additions Strengthen Development and Commercial ExperienceAltimmune added Peter Greenleaf and Alex Horvath to its Board of Directors. Management said they bring experience in drug development, commercialization, and corporate development.
- Cash Position Supports Planned MASH ReadoutThe company ended the quarter with $480 million in cash, cash equivalents, and investments. Management said year-to-date cash burn was tracking in line with plan and was expected to provide operating runway through the PERFORMA Phase 3 MASH 52-week data readout expected in 2029.
DE:3G0 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 03, 2027 | 2026 (Q4) | -0.16- | -0.25 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.12-0.14 | -0.19 | 28.57% (+0.05) | |
| Aug 12, 2026 | 2026 (Q2) | -0.13-0.11 | -0.25 | 55.56% (+0.14) | |
| May 13, 2026 | 2026 (Q1) | -0.22-0.16 | -0.24 | 30.77% (+0.07) | |
| Mar 05, 2026 | 2025 (Q4) | -0.22-0.25 | -0.3 | 18.18% (+0.05) | |
| Nov 06, 2025 | 2025 (Q3) | -0.25-0.19 | -0.29 | 34.38% (+0.10) | |
| Aug 12, 2025 | 2025 (Q2) | -0.31-0.25 | -0.32 | 22.86% (+0.07) | |
| May 13, 2025 | 2025 (Q1) | -0.32-0.24 | -0.31 | 23.53% (+0.07) | |
| Feb 27, 2025 | 2024 (Q4) | -0.30-0.30 | -0.49 | 38.89% (+0.19) | |
| Nov 12, 2024 | 2024 (Q3) | -0.32-0.29 | -0.35 | 17.95% (+0.06) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

